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Background: A growing number of preclinical studies have demonstrated that curcumin 
could be a promising anticancer drug; however, poor bioavailability has been the major 
obstacle for its clinical application. To overcome this problem, we developed a new form of 
curcumin (Theracurmin
®
) and reported high plasma curcumin levels could be safely 
achieved after a single administration of Theracurmin
®
 in healthy volunteers. In this study, 
we aimed to evaluate the safety of repetitive administration of Theracurmin
®
 in cancer 
patients. 
Methods: Pancreatic or biliary tract cancer patients who failed standard chemotherapy were 
eligible for this study. Based on our previous pharmacokinetic study, we selected 
Theracurmin
®
 containing 200 mg of curcumin (Level 1) as a starting dose, and the dose was 
safely escalated to Level 2, which contained 400 mg of curcumin. Theracurmin
® 
was orally 
administered every day with standard gemcitabine-based chemotherapy. In addition to 
safety and pharmacokinetics data, NF-B activity, cytokine levels, efficacy and quality of life 
(QOL) score were evaluated.  
Results: Ten patients were assigned to level 1 and six were to level 2. Peak plasma 
curcumin levels (median) after Theracurmin
®
 administration were 324 ng/mL (range, 
47–1,029 ng/mL) at Level 1 and 440 ng/mL (range, 179–1,380 ng/mL) at Level 2. No 
unexpected adverse events were observed and 3 patients safely continued Theracurmin
®
 
administration for > 9 months.  
Conclusions: Repetitive systemic exposure to high concentrations of curcumin achieved by 
Theracurmin
®
 did not increase the incidence of adverse events in cancer patients receiving 
gemcitabine-based chemotherapy.  
  
Introduction  
Curcumin is a natural polyphenol derived from turmeric (Curcuma longa). In addition to its 
use as food, coloring agent, and traditional medicine, growing evidence suggests that 
curcumin could be a promising anticancer drug [8, 39]. In preclinical studies, curcumin 
exhibits anticancer effects by modulating a variety of molecules involved in cancer 
progression [2, 23, 24, 26, 41]. Curcumin can also potentiate anticancer effects of cytotoxic 
agents [2, 11, 23]. For example, Kunnumakkara et al. demonstrated that combination of 
curcumin with gemcitabine suppressed tumor growth more effectively than curcumin or 
gemcitabine alone using an orthotopic model of pancreatic cancer [23]. Based on these 
promising preclinical data, several investigators, including ourselves, have tested this agent 
in clinical trials [6, 10, 21, 37]. Some clinical benefits were reported; however, plasma 
curcumin levels remained low, despite taking gram doses of curcumin. Administration of 
more than 8 g of curcumin failed to increase plasma curcumin levels in a dose-dependent 
manner in healthy volunteers [42]. Thus, poor bioavailability has been a challenging problem 
for the clinical application of curcumin. To overcome this problem, many attempts are being 
made including the application of innovative drug delivery system (liposome, nanoparticle, 
phospholipids, etc.) or the development of new curcumin analogues [3, 4, 9, 25, 27, 33, 34, 
36]. Among these, a novel form of curcumin (Theracurmin
®
) was developed using a 
microparticle and surface-controlled drug delivery system [33]. Theracurmin
®
 exhibits over 
30-fold higher bioavailability than conventional curcumin in rats. In addition, we verified that 
high plasma curcumin levels can be safely achieved after single administration of 
Theracurmin
®
 in healthy volunteers [19]. Therefore, Theracurmin
®
 could be a useful tool for 
investigating the anticancer effects of curcumin in clinical trials. The few toxicities have 
reported in previous clinical studies; however, this may be attributed to low bioavailability of 
conventional curcumin and the safety of repetitive systemic exposure to high concentrations 
of curcumin remains unclear. Therefore, we planned this phase I study to verify the safety of 
repetitive exposure to high concentrations of curcumin achieved by Theracurmin
®
 in this 
study. In addition to safety and pharmacokinetics data, we evaluated whether the dose 
tested in this study could inhibit NF-B, which is one of the well-known targets of curcumin. 
Cytokine levels, efficacy and quality of life (QOL) score scaled according to the European 
Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire 
(EORTC-QLQ-C30) were also investigated. 
Patients and methods 
Eligibility criteria 
Patients with pancreatic or biliary tract cancer, who failed standard chemotherapy and had 
no other effective treatment option, were eligible if they met the following criteria: histological 
or radiological confirmation of cancer; age ≥20 years; Eastern Cooperative Oncology Group 
performance status of 0–1; adequate bone marrow (neutrophil count ≥1,500/mm3; platelet 
count ≥100,000/mm3), liver [total bilirubin ≤3 mg/dL; aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) ≤150 IU/L], and renal (creatinine ≤1.2 mg/dL) functions; 
adequate oral intake; and provision of written informed consent. Exclusion criteria were 
pulmonary fibrosis or interstitial pneumonia; severe heart disease; uncontrollable diabetes 
mellitus; active infection; pregnancy or lactation; childbearing age in women; severe drug 
hypersensitivity; mental disorder; and other serious medical conditions. This phase I study 
was conducted in two institutions in Japan. The protocol was approved by the review board 
of each institution and registered in the University Hospital Medical Information Network 
Clinical Trials Registry (ID: 000002950). Patient registration and data management were 
conducted in an independent data center at Hokkaido Information University. All procedures 







 was prepared as previously reported [33]. Different from the previous studies, 
we used Theracurmin
®
 in water solution (100 g drink pack) including 0.03% sucralose, 
0.15% citrate acid and 0.1% flavor in this study for the convenience of patients. Each drink 
pack contains 2 and 4 g of Theracurmin (200 and 400 mg of curcumin) for Level 1 and 2, 
respectively, in 100 g water solution.  
 
Treatment 
Planned doses comprised Theracurmin
®
 contains 100, 200, and 400 mg of curcumin for 
Level 0, 1, and 2, respectively. (Theracurmin contains 10 w/w% of curcumin). Level 1 was 
the initial dose selected on the basis of our previous study [19], which proved the safety of 
single administration Theracurmin
®
 containing 210 mg of curcumin in healthy volunteers. 
Daily oral Theracurmin
®
 was added to gemcitabine-based chemotherapy. Fourteen patients 
received gemcitabine/S-1 combination therapy and two received gemcitabine monotherapy. 
Standard dose and schedule of gemcitabine/S-1 chemotherapy consisted of intravenous 
administration of gemcitabine 1000 mg/m
2
 on day 1 and 8, and 60-80 mg/m
2
 of S-1 orally for 
14 consecutive days and repeated every 3 weeks [22]. As for gemcitabine monotherapy, it 
consisted of intravenous administration of gemcitabine 1000 mg/m
2
 on day 1, 8 and 15 
every 4 weeks [5]. The same dose and schedule of gemcitabine-based chemotherapy were 
applied as used before enrollment onto this study. Patients were allowed to take the daily 
Theracurmin
®
 dose at their own convenience, except when monitoring plasma curcumin 
levels on defined days. Gemcitabine-based chemotherapy was initiated and repeated on 
day 1 if the neutrophil count was ≥1,500/mm3; platelet count was ≥75,000/mm3; total 
bilirubin was <3 mg/dL; AST and ALT were <150 U/L; creatinine was <1.5 mg/dL; 
stomatitis/diarrhea was ≤Grade 1; skin rash was ≤Grade 2; and fever was absent (<38°C). If 
patients did not meet the above criteria, gemcitabine-based chemotherapy was delayed by 
1 week or more until recovery. During suspension of gemcitabine-based chemotherapy, 
Theracurmin
®
 administration was also suspended. The dose and schedule of 
gemcitabine-based chemotherapy was adjusted at the discretion of the treating physician 
according to the adverse events observed during the previous cycle. Treatment was 
continued until any of the following occurred: discontinuation of gemcitabine-based 
chemotherapy because of disease progression-based deterioration of general condition; 
Theracurmin
®
 intolerance; unacceptable toxicity related to Theracurmin
®
; >4-week delay of 
the treatment schedule; or patient refusal.  
 
Definition of dose-limiting toxicities and maximum tolerated dose  
Dose-limiting toxicities (DLTs) were determined during the first cycle of concomitant 
gemcitabine-based chemotherapy and defined as ≥Grade 3 nonhematological toxicity 
(except abnormal blood tests) or patient refusal because of Theracurmin
®
 intolerance. If 
only one or two of the six patients experienced DLTs at Level 1—the selected starting 
dose—the dose was escalated to Level 2. No escalation in the dose was allowed in 
individual patients. The maximum tolerated dose (MTD) was defined as that causing DLTs in 
three or more of the six patients. If the MTD had been reached at Level 1, the dose would 
have been planned to be decreased to Level 0 (Theracurmin
®
 containing 100 mg).  
 
Pretreatment and follow-up evaluation 
Pretreatment evaluation included obtaining patient medical history and performing a 
physical examination, complete blood cell count, and serum biochemical tests. Physical 
examinations and blood tests were scheduled on the day of gemcitabine administration. 
Carcinoembryonic antigen and carbohydrate antigen 19-9 were monitored every month. 
Toxicity was evaluated using the Common Toxicity Criteria Adverse Events version 4.0. 
Imaging tests were planned 8 weeks after treatment initiation, and the objective response 
rate was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 in patients with measurable target lesions. Additional imaging tests were 
performed if clinically indicated or at the discretion of the treating physician. 
 
Measurement of plasma curcumin levels by high-performance liquid 
chromatography–mass spectrometry/mass spectrometry 
Plasma curcumin levels were monitored at two time points on day 1 of the second treatment 
cycle (in cases 13 and 16, plasma curcumin levels were monitored on day 1 of the first 
treatment cycle). The first blood draw was performed just before Theracurmin
®
 
administration, representing the nadir. Patients took their daily Theracurmin
®
 dose, and the 
second blood draw was performed 2 h later, representing the peak, according to our 
previous study [19]. Plasma curcumin levels were measured by high-performance liquid 
chromatography-mass spectrometry/mass spectrometry as previously reported [19, 21], and 
the lower limit of detection was 0.5 ng/mL. 
 
NF-B activity 
When developing new target-based drugs, it is desirable to demonstrate that the target can 
be inhibited at the dose administered rather than to determine the MTD [15].  NF-B is one 
of the well-known targets of curcumin [23, 24, 26] and Dhillon et al. reported NF-B inhibition 
in peripheral blood mononuclear cells (PBMCs) after 8 g of conventional curcumin 
administration using immunocytochemistry. Therefore, we selected NF-B as the target of 
Theracurmin
® 
and evaluated the changes of NF-B activity in PBMCs using 
immunocytochemistry. To obtain PBMCs, 8 mL of blood was drawn 2 h after gemcitabine 
administration on day 1 of the first and second cycles. PBMCs were collected using a BD 
Vacutainer
®
 Cell Preparation Tube (Becton, Dickinson and Company, Franklin Lakes, NJ, 
USA) according to the manufacturer’s instructions. Collected PBMCs were then analyzed 
via immunocytochemistry, as previously reported [10]. Anti-human phospho-NF-B p105 
antibody (#4808S; Cell Signaling Technology, Danvers, MA, USA) was chosen.  
 
Cytokine levels 
Anti-inflammatory effect is another property of curcumin [38, 39]. Pro-inflammatory 
cytokines such as interleukin-6 (IL-6) or tumor necrosis factor- (TNF-) are reportedly 
associated with fatigue in cancer patients [28, 35]. Furthermore, curcumin can attenuate the 
expression of these cytokines in vitro [7]. Therefore, we monitored changes in these 
cytokine levels in the blood after Theracurmin
®
 administration in seven patients. Blood 
draws were performed 2 h after gemcitabine administration on day 1 of the first and second 




QOL scores were assessed using the EORTC QLQ-C30 version 3.0 [1, 30]. Patients were 
asked to scale their symptoms on day 1 of each cycle and submit their scoring sheets to an 
independent data center. Scores were translated into scales ranging from 0 to 100 
according to the EORTC QLQ-C30 manual [14]. Five functional scores (emotional, role, 
cognitive, physical, and social) were pooled. A higher score indicates a better symptom for 
functioning and global health status, whereas a lower score indicates a better symptom for 
other items. QOL scores are presented as means ± standard deviations. 
 
Statistical methods 
For statistical analysis, we used the paired Student’s t-test for QOL scores and the 
Mann–Whitney U test for plasma curcumin and cytokine levels. Bonferroni correction was 
made for multiple comparisons of QOL scores, and P < 0.005 was considered significant.  
The final analysis was conducted in October 2012. All statistical analyses were performed 




We enrolled 16 patients between February 2011 and January 2012. Patient characteristics 
are shown in Table 1. Median age was 64 years (range, 50–84 years). Fourteen patients 
had pancreatic cancer and two had biliary tract cancer. All patients previously received 
gemcitabine and S-1 and had no other effective treatment option at enrollment. Median 
number of prior chemotherapies was two (range, 1–4). Theracurmin® was added to 




Detailed information for each patient is summarized in Table 2. Seven patients were 
assigned to Level 1 (Theracurmin
®
 containing 200 mg of curcumin). DLTs in one patient 
(case 2) were unassessable following withdrawal because of disease progression-related 
deterioration in general condition. One patient (case 6) who was taking opioids for 
abdominal cancer pain reported increased abdominal pain after Theracurmin
®
 
administration. We considered this a DLT and discontinued treatment. Another patient (case 
3) reported increased abdominal pain during the second treatment cycle. This did not meet 
the DLT criteria because the complaint developed during the second treatment cycle. 
Computed tomography (CT) revealed deterioration of peritonitis carcinomatosa to be the 
likely cause of abdominal pain; however, we consulted with the data and safety monitoring 
committee and assigned three additional patients to Level 1 to evaluate the association 
between increased abdominal pain and Theracurmin
®
 administration. None of these 
patients reported abdominal pain. Therefore, we escalated the dose to Level 2 
(Theracurmin
®
 containing 400 mg of curcumin). Six patients were assigned to Level 2. DLTs 
in one patient (case 16) were unassessable following withdrawal because of disease 




The overall adverse events are summarized in Table 3. Grade 3–4 neutropenia, leucopenia, 
anemia, and thrombocytopenia were observed in 38%, 38%, 13%, and 0% of Level 1 
patients, and 20%, 20%, 40%, and 0% of Level 2 patients, respectively. Excluding two cases 
of Grade 3 abdominal pain mentioned previously, other Grade 3–4 nonhematological 
adverse events included Grade 3 infection (n = 1) at Level 1 and Grade 3 elevated alkaline 
phosphatase (n = 1) at Level 2. Both of these were likely attributable to disease progression. 
Three patients (cases 1, 8, and 14) continued Theracurmin
®
 administration for >9 months. 
We observed no unexpected adverse events attributable to long-term Theracurmin
®
 
administration in these three patients. 
 
Plasma curcumin levels 
We measured plasma curcumin levels in 14 patients. Median plasma curcumin levels 
immediately before Theracurmin
®
 administration on day 1 of the second treatment cycle 
(representing the nadir) were 71 ng/mL (range, <5–208 ng/mL) at Level 1 and 129 ng/mL 
(range, 50–192 ng/mL) at Level 2. Median plasma curcumin levels 2 h after Theracurmin® 
administration (representing the peak) were 324 ng/mL (range, 47–1,029 ng/mL) at Level 1 
and 440 ng/mL (range, 179–1,380 ng/mL) at Level 2 (Figure 1). Therefore, Theracurmin® 
could safely increase plasma curcumin levels in a dose-dependent manner.  
 
NF-B activity 
NF-B is one of the well-known targets of curcumin [23, 24, 26]. To determine whether 
NF-B activity is inhibited at the dose tested in this study, we evaluated the changes of 
NF-B activity in PBMCs using immunocytochemistry as previously reported [10]. 
Unfortunately, we could not clearly demonstrate significant changes in NF-B activity after 
Theracurmin
®
 administration (data not shown).  
 
Cytokines 
Anti-inflammatory effect is another property of curcumin [38, 39]. Pro-inflammatory 
cytokines such as interleukin-6 (IL-6) or tumor necrosis factor- (TNF-) are reportedly 
associated with fatigue in cancer patients [28, 35]. Furthermore, curcumin can attenuate the 
expression of these cytokines in vitro [7]. Therefore, we monitored changes in these 
cytokine levels in the blood after Theracurmin
®
 administration in seven patients. Median IL-6 
levels in the plasma before and after Theracurmin
®
 administration were 3.4 pg/mL (range, 
1.8–10.8 pg/mL), and 4.4 pg/mL (range, 2.0–12.0 pg/mL), respectively. Similarly, median 
TNF- levels were 1.1 pg/mL (range, 0.6–2.9 pg/mL), and 1.3 pg/mL (range, 0.8–2.9 pg/mL), 
respectively. Therefore, no significant change in cytokine levels was observed among the 
seven evaluated patients. 
 
Efficacy  
Of the 12 evaluable patients, none experienced a partial or complete response, and three 
(25%) demonstrated stable disease according to RECIST. All of the 14 patients with 
pancreatic cancer died at the time of final analysis. The median survival time (MST) was 132 




Complete EORTC QLQ-C30 scores on day 1 of the first treatment cycle (baseline) and on 
day 1 of the second or later treatment cycles were available in 12 patients. Three patients 
could not submit the score sheet after Theracurmin
®
 administration because of withdrawal 
or DLTs, and one failed to complete the score sheet. Changes in QOL scores after 
Theracurmin
®
 administration are summarized in Table 4. Fatigue- and 
functioning-associated QOL scores significantly improved after Theracurmin
®
 administration, 
even after adjustment for multiple comparisons (Table 4). The appetite-associated QOL 
score also improved by 16.7, although this difference was not statistically significant.  
 
Discussion  
A growing number of preclinical studies have demonstrated curcumin could be a promising 
anticancer drug  [2, 23, 24, 26, 41]; however, poor bioavailability has been the major 
obstacle for the clinical application of curcumin. To overcome this problem, Theracurmin
®
 
was developed using a microparticle and surface-controlled drug delivery system and 
demonstrated over 30-fold higher bioavailability than conventional curcumin in rats [33]. 
Furthermore, we previously reported that high plasma curcumin levels could be safely 
achieved after a single administration of Theracurmin
®
 in healthy volunteers [19]. The few 
toxicities have reported in previous clinical studies testing curcumin; however, this may be 
attributed to low bioavailability of conventional curcumin and the safety of repetitive systemic 
exposure to high concentrations of curcumin remains unclear. Therefore, we planned this 
study to determine whether repetitive Theracurmin
®
 administration could safely increase 
plasma curcumin levels in cancer patients. Median plasma curcumin levels 2 h after 
Theracurmin
®
 administration (representing peak levels) were 324 ng/mL (range, 47–1,029 
ng/mL) at Level 1 (Theracurmin
®
 containing 200 mg of curcumin) and 440 ng/mL (range, 
179–1,380 ng/mL) at Level 2 (Theracurmin® containing 400 mg of curcumin). These values 
were significantly higher than the median values (85 ng/mL) achieved in our previous study 
using 8 g of conventional curcumin [21]. Interpatient variability was large and peak plasma 
curcumin levels did not increase as expected in some patients. This may be partly 
attributable to delayed gastric emptying caused by surgery for primary cancer [13] or to the 
primary cancer itself. For example, endoscopic examination revealed pyloric stenosis 
caused by pancreatic cancer invasion in case 7 and this may have caused the low plasma 
curcumin levels in this patient. We could monitor plasma curcumin levels after Theracurmin
®
 
administration for >6 months in cases 1 and 8. Plasma curcumin levels 0 and 2 h after 
Theracurmin
®
 administration were 238 and 1,176 ng/mL, respectively, in case 1 (monitored 
at 9 months) and 260 and 935 ng/mL, respectively, in case 8 (monitored at 7 months). 
Interestingly, these values were much higher than those observed on day 1 of the second 
cycle (Table 2), suggesting that Theracurmin
®
 bioavailability cumulatively increases after 
repeated administration. Vareed et al. mentioned that repeated daily administration of 
curcumin may cause its accumulation at the mucosal surface and increase plasma levels 
[42]. Further studies are necessary to verify this hypothesis.  
Regarding safety, two patients reported increased abdominal pain after Theracurmin
®
 
administration. CT scan before Theracurmin
®
 administration in these patients revealed 
dilated colons, which could be attributed to intestinal obstruction caused by peritonitis 
carcinomatosa. Consistent with our observations, Epelbaum et al. also reported abdominal 
fullness or pain related to curcumin administration in patients with pancreatic cancer [12]. 
We speculate that curcumin irritates the intestine, potentially increasing abdominal pain in 
patients with intestinal obstruction due to peritonitis carcinomatosa or other reasons. In 
future clinical trials, we advise caution in administering curcumin to such patients.  
Other toxicities were comparable with those of gemcitabine-based chemotherapy [22] and 
the repetitive exposure to high concentrations of curcumin did not cause unexpected serious 
adverse events or increase the incidence of adverse events in patients with pancreatic or 
biliary tract cancer receiving gemcitabine-based chemotherapy.  
Regarding efficacy, no responses were observed in this study according to RECIST; 
however, the MST was 132 days (95% confidence interval: 53–210 days) for 14 patients 
with pancreatic cancer and three patients (21%) survived for >12 months. We believe that 
these results are promising, considering the poor prognosis of patients with pancreatic 
cancer who received only best supportive care after progression on gemcitabine [31]. 
In our previous study [21], some patients reported improved QOL after curcumin 
administration. In line with our observation, Sharma et al. reported QOL improvement after 
curcumin administration [37]. Therefore, we prospectively assessed QOL scores using 
EORTC QLQ-C30, which is widely accepted as a standard tool to evaluate QOL [1, 30]. 
Consistent with previous observations, fatigue- and functioning-associated QOL scores 
significantly improved during Theracurmin
®
 administration, even after adjustment for 
multiple comparisons. In five patients, the fatigue score improved by >20, which is 
interpreted as a significant and clinically relevant change [30]. Preclinical studies 
demonstrating the benefit of curcumin on heart failure, depression, and fatigue [17, 29, 43] 
support our current findings. Since improved QOL has been demonstrated to contribute to a 
better outcome in cancer patients [40], it is tempting to speculate that Theracurmin
®
 can 
improve the outcome of cancer patients through an improvement in QOL. A randomized 
placebo-controlled clinical trial enrolling a larger cohort is warranted to verify this hypothesis. 
Most of the orally administered curcumin is metabolized into curcumin glucuronide and 
curcumin sulfate and only little amount of parent curcumin exist in plasma [18]. Some group 
claimed that high plasma curcumin levels achieved by Theracurmin
®
 were clinically 
irrelevant because these were of curcumin conjugates [16]. We have responded to this 
comment and shown some reports supporting our data [20]. Vareed et al. has proposed that 
conjugated curcumin can exert its activity after deconjugation at the target sites [42]. Pfeiffer 
et al. demonstrated that conjugated curcumin itself holds some important biological 
functions [32]. Therefore, we believe that high plasma curcumin levels achieved by 
Theracurmin
®
 can potentially improve the anticancer effects of this agent in cancer patients. 
When developing new target-based drugs, it is desirable to demonstrate that the target can 
be inhibited at the dose administered rather than to determine the MTD, which is the 
conventional endpoint for cytotoxic drugs [15].  NF-B is one of the well-known targets of 
curcumin [23, 24, 26] and Dhillon et al. reported NF-B inhibition in PBMCs after 8 g of 
conventional curcumin administration using immunocytochemistry [10]. Therefore, we 
selected NF-B as the target of Theracurmin
®
 and evaluated the changes of NF-B activity 
in PBMCs using immunocytochemistry. In contrast to the report by Dhillon et al., we could 
not observe the significant change of NF-B activity in PBMCs. The reasons for this 
discrepancy between our results and those of Dhillon et al. remain unclear. Because we 
could achieve higher plasma curcumin levels compared with those reported by Dhillon et al. 
(maximum concentration ≤125 ng/mL), plasma curcumin level was unlikely to be a major 
reason. Evaluation of NF-B activity in tumor tissues is preferable; however, there exist 
ethical problems for repeating a tumor biopsy in patients with pancreatic or biliary tract 
cancer because of its invasiveness. Optimal dose of Theracurmin
®
 to exert anticancer 
effects remains to be clarified in the future studies. 
In summary, repetitive systemic exposure to high concentrations of curcumin achieved by 
Theracurmin
®
 did not increase the incidence of adverse events in cancer patients receiving 
gemcitabine-based chemotherapy.  
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Table 1. Patient characteristics 
 
Total no. of patients enrolled 16 
No. of patients evaluated for DLT 14 
No. of patients evaluated for QOL 12 
Gender 
 
    Male 11 (68%) 
    Female 5 (32%) 
Median age (years) 64 (range 50–84) 
Tumor type 
 
    Pancreas 14 (87%) 
    Biliary tract 2 (13%) 
Disease status 
 
    Unresectable 7 (44%) 
    Recurrent 9 (56%) 
Prior no. of chemotherapies 
 
   1 3 (19%) 
   2 11 (69%) 
   ≥3 2 (13%) 
Concomitant regimen 
 
    GEM/S-1 14 (87%) 
    GEM 2 (13%) 
Performance status  
 
   0 9 (57%) 
   1 7 (43%) 
Median CEA (ng/mL)    15 (range 2–258) 






Table 2. Detailed information and plasma curcumin levels in each patient 
 
      
 
















RECIST 0 h 2 h 
1 1 56 male Pancreas 0 1 yes GEM/S-1 1.60  33 288 SD 
2 1 70 male Pancreas 1 2 yes GEM/S-1 1.62  88 361 PD 
3 1 66 male Pancreas 1 2 no GEM/S-1 1.44  NE NE NE 
4 1 72 male Pancreas 0 2 yes GEM/S-1 1.52  8 145 PD 
5 1 57 female Biliary tract   0 3 yes GEM/S-1 1.67  103 379 PD 
6 1 54 male Pancreas 0 1 no GEM/S-1 1.57  NE NE NE 
7 1 72 male Pancreas 0 4 no GEM/S-1 1.60  53 47 PD 
8 1 59 female Pancreas 0 2 no GEM/S-1 1.57  112 406 SD 
9 1 82 male Pancreas 1 2 yes GEM/S-1 1.47  208 165 NE 
10 1 69 male Pancreas 0 2 yes GEM 1.62  <5*
1
 1,029 PD 
11 2 62 female Pancreas 1 1 no GEM/S-1 1.38  89 251 PD 
12 2 61 female Pancreas 1 2 yes GEM/S-1 1.32  168 498 PD 
13 2 84 male Pancreas 1 2 yes GEM 1.52  <5*
1, 2
 1,380 PD 
14 2 59 male Pancreas 0 2 no GEM/S-1 2.06  50 383 SD 
15 2 50 female Biliary tract   0 2 yes GEM 1.31  192 179 PD 
16 2 67 male Pancreas 1 2 no GEM 1.65  <5*
1, 2
 536 NE 
BSA body surface area  *1 Below the lower limit of detection; *2 Plasma curcumin levels were monitored on day 1 of the first cycle 
     
3 
 
Table 3. Toxicities 
    
 
Level 1 (n = 8) Level 2 (n = 5) 
 
Gr 1–2 Gr 3–4 Gr 1–2 Gr 3–4 
Neutropenia 2 3 1 1 
Leucopenia 3 3 1 1 
Anemia 7 1 1 2 
Thrombocytopenia 6 0 0 0 
Febrile neutropenia NA 0 NA 0 
Anorexia 2 0 2 0 
Nausea 1 0 0 0 
Vomiting 2 0 0 0 
Fatigue 2 0 1 0 
Diarrhea 3 0 0 0 
Stomatitis 3 0 0 0 
Constipation 2 0 2 0 
Fever 3 0 1 0 
Infections (others) 0 1 0 0 
Biliary tract infection NA 0 NA 0 
AST 6 0 2 0 
ALT 4 0 2 0 
Albumin 8 0 4 0 
Hyperbilirubinemia 2 0 0 0 
Creatinine 0 0 0 0 
Alkaline phosphatase 5 0 2 1 




Table 4. Changes in quality of life scores 











Fatigue score 38.0 ± 13.2 24.8 ± 14.3 −13.2 0.004 
Functional score*
1,2
 82.8 ± 11.9 90.7 ± 8.1 8.0 0.001 
Diarrhea 15.0 ± 27.6 5.6 ± 12.4 −9.4 0.006 
Financial difficulties 16.7 ± 25.5 2.8 ± 9.2 −13.9 0.027 
Appetite loss 38.9 ± 26.6 22.2 ± 28.3 −16.7 0.026 
Insomnia 13.9 ± 16.4 8.3 ± 14.4 −5.6 0.083 
Pain 22.2 ± 19.6 16.7 ± 18.0 −5.5 0.083 
Nausea 6.9 ± 10.7 2.8 ± 4.2 −4.1 0.096 
Constipation 19.4 ± 21.3 11.1 ± 20.8 −8.3 0.214 
Dyspnea 25.0 ± 27.6 16.7 ± 21.5 −8.3 0.215 
Global health*
2
 56.3 ± 18.7 63.2 ± 20.0 6.9 0.101 
*1 Five functional scores (emotional, role, cognitive, physical, and social functions) were pooled together 
*2 A higher score indicates a better symptom; otherwise, a lower score indicates a better symptom 




Figure 1. Plasma curcumin levels 2 h after Theracurmin
®
 administration. Each point 
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